

Freedom of Information Request	FOI 22-287	18 th July 2022
--------------------------------	------------	----------------------------

I would be grateful if you would please answer the following questions concerning antifungal treatment within your organisation.

1) What is the number of patients in the last 12 months treated with the following product lines:

- A) anidulafungin**
- B) caspofungin**
- C) micafungin**

Please find below the quantities dispensed from the Health Board pharmacies for the period June 2021 to May 2022 for any disease. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

	Quantity
ANIDULAFUNGIN 100 mg Intravenous Infusion 1 Vial Pack	39
CASPOFUNGIN 50 mg Intravenous Infusion 1 Vial Pack	457
CASPOFUNGIN 70 mg Intravenous Infusion 1 Vial Pack	472
MICAFUNGIN 50 mg Intravenous Infusion 1 Vial Pack	21
MICAFUNGIN 100 mg Intravenous Infusion 1 Vial Pack	20

2) What is the split of indication over the last 12 months for the following product lines:

- A) anidulafungin**
- B) caspofungin**
- C) micafungin**

Please find below the split of indication for quantities dispensed from the Health Board pharmacies for the period June 2021 to May 2022 for any disease. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

		Quantity
ANIDULAFUNGIN 100 mg Intravenous Infusion 1 Vial Pack	General Surgery	23
	Stroke	14
	Care of the Elderly	2
CASPOFUNGIN 50 mg Intravenous Infusion 1 Vial Pack	Gynaecology	1
	Children's Paediatric Services	7
	General Surgery	188
	Urology	26
	Critical Care & Resus	98

	RGH Acute Medicine	1
	Gastroenterology	99
	Stroke	14
	Respiratory	23
CASPOFUNGIN 70 mg Intravenous Infusion 1 Vial Pack	General Surgery	126
	Urology	7
	Critical Care & Resus	283
	NHH AMU	3
	RGH Acute Medicine	1
	Gastroenterology	5
	Stroke	5
	Care of the Elderly	14
	Respiratory	28
MICAFUNGIN 50 mg Intravenous Infusion 1 Vial Pack	Respiratory	21
MICAFUNGIN 100 mg Intravenous Infusion 1 Vial Pack	Respiratory	20

3) For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated.